Evidence-Based Complementary and Alternative Medicine

Research Article

Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial

Table 1

Baseline status.
 Group values
 HxA
( )		Control
( )
Age in years (mean ± SD; -test) 0.228
Tumor status ( ; Chi square test)   
 Tumor classification   0.619
  T199 
  T22419 
  T312 
  T 01 
 Pos. lymph nodes  0.849
  N01616 
  N11614 
  N221 
 Tumor grade  0.474
  G131 
  G22824 
  G336 
 Menopause status ( ; Kruskal-Wallis test)  0.475
  Premenopausal1813 
  Perimenopausal21 
  Postmenopausal1317 
  Unknown10 
 Receptor status estrogen  0.507
  Positive2117 
  Negative912 
  unknown42 
 Receptor status progesterone  0.620
  Positive2219 
  Negative810 
  Unknown42 
Body Mass Index (mean ± SD; -test) 0.709
Karnofsky-Index (mean ± SD) —
Abnormal findings on physical examination ( )00—
Vital signs (mean ± SD; -test)   
 Blood pressure systolic (mmHg) 0.139
 Blood pressure diastolic (mmHg) 0.209
 Pulse (/min) 0.945
 Temperature (°C) 1.000
Primary outcomes    
 EORTC QLQ-C30
(mean ± SD; Mann-Whitney -test)		   
  Global health status 0.713
  Physical functioning 0.872
  Role functioning 0.443
  Emotional functioning 0.274
  Cognitive functioning 0.23
  Social functioning 0.226
  Fatigue 0.894
  Nausea and vomiting 0.285
  Pain 0.273
  Dyspnea 0.839
  Insomnia 0.902
  Appetite loss 0.704
  Constipation 0.914
  Diarrhoea 0.498
  Financial difficulties 0.661
Secondary outcomes    
 Incidence of neutropenia 00—